Pulsenmore Ltd.

424B3 priced

3,125,000 shares

The current 424B3 filing focuses on corporate governance details for Pulsenmore Ltd., emphasizing shareholder meeting procedures, voting rights, and regulatory compliance under Israeli law. It outlines requirements for annual/special meetings, quorum thresholds, voting majorities, and shareholder access to corporate records. The document also details rules for tender offers, mergers, and private placements, highlighting the company's adherence to Israeli Companies Law and its implications for shareholder approvals and corporate actions.

EFFECT effective

F-1 filed

3,125,000 shares

The current filing for Pulsenmore Ltd. (F-1) outlines corporate governance structures, shareholder meeting procedures, voting rights, and legal compliance under Israeli law. It details requirements for annual and special meetings, quorum thresholds, voting majorities, and shareholder access to corporate records. The document emphasizes procedural frameworks for shareholder engagement, director appointments, and compliance with Israeli Companies Law, including tender offer regulations and merger provisions.

20-F supplemental

Pulsenmore Ltd. filed a 20-F annual report for the fiscal year ending December 31, 2025. The filing includes financial data, share details, and corporate information. The company is based in Israel, with operations and financial activities reported in multiple currencies. Key elements include revenue recognition, research and development expenses, and corporate governance details.

CERT inactive

Pulsenmore Ltd. is preparing for its initial public offering (IPO) with a current filing (CERT) submitted on 2026-01-20, following a prior DRS/A filing. The company, incorporated in Israel in 2014, is seeking listing on the Nasdaq Capital Market. The filing includes financial statements prepared under IFRS, with the New Israeli Shekel as the functional currency. Key details from the previous filing highlight risks related to market competition, regulatory changes, and cybersecurity, though the current filing's content remains limited in the provided text.

DRS/A amended

Pulsenmore Ltd. filed a DRS/A registration statement with the SEC on 2025-09-29, seeking to list its ordinary shares on the Nasdaq Capital Market. The filing includes financial statements prepared under IFRS, with disclosures about forward-looking statements and material risks. The company, incorporated in Israel in 2014, previously listed on TASE and now aims for U.S. market access. Key details include capital structure, regulatory compliance risks, and geopolitical exposures.

DRS/A amended

Pulsenmore Ltd. filed an Amendment No. 3 to its Form 20-F registration statement for an upcoming IPO on the Nasdaq Capital Market. The filing includes updated financial statements prepared under IFRS, details about the company's history since 2014, and disclosures regarding risks, corporate governance, and regulatory compliance. The company anticipates listing its ordinary shares under the ticker symbol PUES.

DRS/A amended

Pulsenmore Ltd. is an Israeli company incorporated in 2014, listed on the Tel Aviv Stock Exchange (TASE) under the symbol PULS. It is preparing to list its ordinary shares on the Nasdaq Capital Market. The filing includes financial statements prepared under IFRS, with the New Israeli Shekel as the reporting currency. The company highlights risks related to its lack of operating history, capital requirements, market expansion, and regulatory compliance.

DRS/A amended

Pulsenmore Ltd. filed an amended registration statement (DRS/A) for its upcoming Nasdaq listing, building on its existing TASE listing. The filing includes financial statements prepared under IFRS, highlights risks related to its early-stage operations, and outlines forward-looking statements. The company seeks to transition to U.S. market listing, with details on its capital structure, business operations, and regulatory compliance.

DRS filed

Pulsenmore Ltd., incorporated in 2014 under Israeli law, is preparing to list its ordinary shares on the Nasdaq Capital Market. The company's financial statements are prepared under IFRS, with the New Israeli Shekel as the reporting currency. The filing includes forward-looking statements and outlines risks related to its early-stage operations, capital requirements, and market expansion. The company is led by CEO Dr. Elazar Sonnenschein and has engaged legal and auditing firms for the offering.